ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: Pasireotide Works Well In Acromegaly Trial

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the company said Monday. Patients treated with pasireotide LAR, or SOM230, were 63% more likely to achieve control of their disease than those treated with Novartis' Sandostatin LAR, or octreotide, the study showed. The safety profile of pasireotide LAR was similar to that of octreotide LAR, known under the brand name Sandostatin, with the exception of a higher degree of hyperglycemia, Novartis said. "The positive results seen in the Phase III trial point to the potential role of pasireotide LAR in treating patients with acromegaly, a condition for which there remains an unmet need," said Herve Hoppenot, president of Novartis Oncology, in a statement. "These findings are welcome news as we continue our research efforts to discover treatments for patients with pituitary-related conditions." Acromegaly, a rare endocrine disorder caused by excess growth hormone, can result in enlarged hands, feet and internal organs, and increased risk of death. Novartis said the data were presented at the 15th International Congress of Endocrinology and 14th European Congress of Endocrinology meeting in Florence, Italy. The medical meeting runs from May 5 to May 9. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
06/06/201605:11:00Mereo BioPharma to Trade on AIM -- Update
05/23/201616:40:00Samsung Targets U.S. Drug Market With Remicade Knockoff
05/20/201615:20:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/20/201615:18:00Colombia Threatens to Override Novartis's Patent on Gleevec
05/18/201603:03:00Novartis Says Drug-Unit Chief To Leave Firm -- WSJ
05/17/201618:43:00ADRs End Lower; NQ Mobile Rises
05/17/201615:11:00Novartis to Split Pharmaceuticals Division into Two -- Update
05/17/201614:10:00Novartis to Split Drug Division
05/17/201613:27:00Novartis to Split Pharmaceuticals Division Into Two
05/05/201620:58:00Upsized IPO of Biotech Company Intellia Prices at Top of Range
05/03/201608:30:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
05/03/201608:19:00Shannon Klinger to Replace Eric Cornut as Novartis's Ethics Officer
04/29/201604:50:00AstraZeneca's Investment Eats Into Profit
04/28/201616:40:00Amgen Profit Rises 17%, Guidance Raised
04/27/201608:20:00GlaxoSmithKline Sees First-Quarter Profit Fall
04/26/201608:10:00Eli Lilly Revenue Boosted By New Drug Sales
04/22/201603:03:00Novartis Feels the Effect Of Drop in Gleevec Sales -- WSJ
04/21/201608:29:00Novartis Earnings Fall on Slide in Cancer-Drug Sales -- 2nd Update
04/21/201603:50:00Novartis Earnings Fall on Slide in Cancer-Drug Sales --Update
04/21/201602:10:00Novartis Earnings Fall on Slide in Cancer-Drug Sales

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad